Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure-Reference-Cited by-同舟云学术

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure

Published:2019-01-15 Issue:3 Volume:139 Page:362-365
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Zannad Faiez¹,Rossignol Patrick¹

Affiliation:

1. Université de Lorraine, Cardiovascular and Renal Clinical Trialists, Nancy, France.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference16 articles.

1. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death

2. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. https://www.fda.gov/downloads/Drugs/Guidances/ucm071627.pdf. Accessed December 21 2018.

3. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion

4. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored

5. Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Nine Dipeptidyl Peptidase-4 Inhibitors from Coptis chinensis Using Virtual Screening, Bioactivity Evaluation, and Binding Studies;Molecules;2024-05-14

2. Risk Assessment for Heart Failure in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase 4 Inhibitor Using a Large Claims Dataset;Biological and Pharmaceutical Bulletin;2023-09-01

3. DPP4 as a Potential Candidate in Cardiovascular Disease;Journal of Inflammation Research;2022-09

4. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials;BMJ;2022-06-28

5. Scientific and ethical issues in add-on designs for antidiabetic drugs;European Journal of Clinical Pharmacology;2022-06-22